169 related articles for article (PubMed ID: 31638797)
1. Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy.
Marcoux D; Duan JJ; Shi Q; Cherney RJ; Srivastava AS; Cornelius L; Batt DG; Liu Q; Beaudoin-Bertrand M; Weigelt CA; Khandelwal P; Vishwakrishnan S; Selvakumar K; Karmakar A; Gupta AK; Basha M; Ramlingam S; Manjunath N; Vanteru S; Karmakar S; Maddala N; Vetrichelvan M; Gupta A; Rampulla RA; Mathur A; Yip S; Li P; Wu DR; Khan J; Ruzanov M; Sack JS; Wang J; Yarde M; Cvijic ME; Li S; Shuster DJ; Borowski V; Xie JH; McIntyre KW; Obermeier MT; Fura A; Stefanski K; Cornelius G; Hynes J; Tino JA; Macor JE; Salter-Cid L; Denton R; Zhao Q; Carter PH; Dhar TGM
J Med Chem; 2019 Nov; 62(21):9931-9946. PubMed ID: 31638797
[TBL] [Abstract][Full Text] [Related]
2. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
Lu Z; Duan JJ; Xiao H; Neels J; Wu DR; Weigelt CA; Sack JS; Khan J; Ruzanov M; An Y; Yarde M; Karmakar A; Vishwakrishnan S; Baratam V; Shankarappa H; Vanteru S; Babu V; Basha M; Kumar Gupta A; Kumaravel S; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
Bioorg Med Chem Lett; 2019 Aug; 29(16):2265-2269. PubMed ID: 31257087
[TBL] [Abstract][Full Text] [Related]
3. Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists.
Jiang B; Duan JJ; Stachura S; Karmakar A; Hemagiri H; Raut DK; Gupta AK; Weigelt CA; Khan J; Sack JS; Wu DR; Yarde M; Shen DR; Galella MA; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Dhar TGM
Bioorg Med Chem Lett; 2020 Sep; 30(17):127392. PubMed ID: 32738966
[TBL] [Abstract][Full Text] [Related]
4. Discovery of carbazole carboxamides as novel RORγt inverse agonists.
Huang Y; Yu M; Sun N; Tang T; Yu F; Song X; Xie Q; Fu W; Shao L; Wang Y
Eur J Med Chem; 2018 Mar; 148():465-476. PubMed ID: 29477887
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Biological Evaluation of Retinoic Acid-Related Orphan Receptor γt (RORγt) Agonist Structure-Based Functionality Switching Approach from In House RORγt Inverse Agonist to RORγt Agonist.
Yukawa T; Nara Y; Kono M; Sato A; Oda T; Takagi T; Sato T; Banno Y; Taya N; Imada T; Shiokawa Z; Negoro N; Kawamoto T; Koyama R; Uchiyama N; Skene R; Hoffman I; Chen CH; Sang B; Snell G; Katsuyama R; Yamamoto S; Shirai J
J Med Chem; 2019 Feb; 62(3):1167-1179. PubMed ID: 30652849
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Interleukin-23-Mediated Inflammation with a Novel Small Molecule Inverse Agonist of ROR
Gauld SB; Jacquet S; Gauvin D; Wallace C; Wang Y; McCarthy R; Goess C; Leys L; Huang S; Su Z; Edelmayer R; Wetter J; Salte K; McGaraughty SP; Argiriadi MA; Honore P; Luccarini JM; Bressac D; Desino K; Breinlinger E; Cusack K; Potin D; Kort ME; Masson PJ
J Pharmacol Exp Ther; 2019 Oct; 371(1):208-218. PubMed ID: 31375639
[TBL] [Abstract][Full Text] [Related]
7. Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.
Narjes F; Xue Y; von Berg S; Malmberg J; Llinas A; Olsson RI; Jirholt J; Grindebacke H; Leffler A; Hossain N; Lepistö M; Thunberg L; Leek H; Aagaard A; McPheat J; Hansson EL; Bäck E; Tångefjord S; Chen R; Xiong Y; Hongbin G; Hansson TG
J Med Chem; 2018 Sep; 61(17):7796-7813. PubMed ID: 30095900
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists.
Lu L; Chen S; Yu M; Zhou R; Guo S; Chen JA; Wang H; Chen S; Luo C; Xie Q; Wang Y
Eur J Med Chem; 2023 Aug; 256():115424. PubMed ID: 37167779
[TBL] [Abstract][Full Text] [Related]
9. Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists.
Sun N; Huang Y; Yu M; Zhao Y; Chen JA; Zhu C; Song M; Guo H; Xie Q; Wang Y
Eur J Med Chem; 2020 Sep; 202():112536. PubMed ID: 32698100
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-indanyl benzamides as potent RORγt inverse agonists.
Tian J; Sun N; Yu M; Gu X; Xie Q; Shao L; Liu J; Liu L; Wang Y
Eur J Med Chem; 2019 Apr; 167():37-48. PubMed ID: 30743096
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Biaryl Amide Derivatives as Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.
Lu L; Huang Y; Song M; Sun N; Xia L; Yu M; Zhao M; Qiu R; Chen JA; Zhao Y; Wang H; Guo H; Li Y; Zhu D; Wang Y; Xie Q
J Med Chem; 2023 Dec; 66(23):16091-16108. PubMed ID: 37982494
[TBL] [Abstract][Full Text] [Related]
12. Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists.
Meijer FA; Doveston RG; de Vries RMJM; Vos GM; Vos AAA; Leysen S; Scheepstra M; Ottmann C; Milroy LG; Brunsveld L
J Med Chem; 2020 Jan; 63(1):241-259. PubMed ID: 31821760
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists.
Wang Y; Yang T; Liu Q; Ma Y; Yang L; Zhou L; Xiang Z; Cheng Z; Lu S; Orband-Miller LA; Zhang W; Wu Q; Zhang K; Li Y; Xiang JN; Elliott JD; Leung S; Ren F; Lin X
Bioorg Med Chem; 2015 Sep; 23(17):5293-302. PubMed ID: 26277758
[TBL] [Abstract][Full Text] [Related]
14. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists.
Sato A; Fukase Y; Kono M; Ochida A; Oda T; Sasaki Y; Ishii N; Tomata Y; Fukumoto S; Imai YN; Uga K; Shibata A; Yamasaki M; Nakagawa H; Shirasaki M; Skene R; Hoffman I; Sang BC; Snell G; Shirai J; Yamamoto S
ChemMedChem; 2019 Nov; 14(22):1917-1932. PubMed ID: 31659845
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Design and Synthesis of Fluorene Derivatives as Novel RORγt Inverse Agonists.
Gabr MT; Abdel-Raziq MS
Chem Biodivers; 2018 Sep; 15(9):e1800244. PubMed ID: 29935095
[TBL] [Abstract][Full Text] [Related]
17. Annulation reaction enables the identification of an exocyclic amide tricyclic chemotype as retinoic acid Receptor-Related orphan receptor gamma (RORγ/RORc) inverse agonists.
Marcoux D; Bertrand MB; Weigelt CA; Yip S; Galella M; Park H; Wu DR; Wang J; Yarde M; Cvijic ME; Li S; Hynes J; Tino JA; Zhao Q; Dhar TGM
Bioorg Med Chem Lett; 2020 Oct; 30(19):127466. PubMed ID: 32763309
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 2,6-difluorobenzyl ether series of phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfones as surprisingly potent, selective and orally bioavailable RORγt inverse agonists.
Duan JJ; Jiang B; Lu Z; Stachura S; Weigelt CA; Sack JS; Khan J; Ruzanov M; Wu DR; Yarde M; Shen DR; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
Bioorg Med Chem Lett; 2020 Oct; 30(19):127441. PubMed ID: 32736080
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel quinazolinedione derivatives as RORγt inverse agonist.
Fukase Y; Sato A; Tomata Y; Ochida A; Kono M; Yonemori K; Koga K; Okui T; Yamasaki M; Fujitani Y; Nakagawa H; Koyama R; Nakayama M; Skene R; Sang BC; Hoffman I; Shirai J; Yamamoto S
Bioorg Med Chem; 2018 Feb; 26(3):721-736. PubMed ID: 29342416
[TBL] [Abstract][Full Text] [Related]
20. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors.
Li X; Anderson M; Collin D; Muegge I; Wan J; Brennan D; Kugler S; Terenzio D; Kennedy C; Lin S; Labadia ME; Cook B; Hughes R; Farrow NA
J Biol Chem; 2017 Jul; 292(28):11618-11630. PubMed ID: 28546429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
